AZNCF News and Press, AstraZeneca Plc From 05/30/24

2024-05-30 09:14:24 ET Summary Data update from phase 1 BALLI-01 study, using UCART22 for the treatment of B-cell acute lymphoblastic leukemia, expected by the end of 2024. The global acute lymphoblastic leukemia therapeutics market is expected to increase to $8.29 billion by 2032...

2024-05-26 02:45:00 ET Summary Jiangsu Hengrui Medicine out-licenses global rights for its GLP-1 candidates to US startup Hercules in a deal worth up to $6 billion. Shanghai Degron Therapeutics partners with Takeda to identify multiple targets in oncology, neuroscience, and inflam...

2024-05-24 07:00:00 ET Summary AstraZeneca reported Q1 2024 earnings of $12.7bn, up 19% YoY, and EPS of $2.06, up 13% YoY. The company aims to achieve $80bn in total revenue by 2030, up from $45.8bn in 2023. AZN plans to launch 20 new medicines by 2030, many with the potential...

2024-05-23 12:36:52 ET Summary Lantheus Holdings, Inc. excels in radiopharmaceuticals, with PYLARIFY's dominance in PSMA PET imaging. The market for radiopharmaceuticals is expanding beyond all expectations by both industry experts and the company's management. Lantheus is act...

2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...

2024-04-25 12:20:08 ET AstraZeneca PLC (AZN) Q1 2024 Earnings Conference Call April 25, 2024 06:45 AM ET Company Participants Andy Barnett - Head of Investor Relations Pascal Soriot - Executive Director and Chief Executive Officer Aradhana Sarin - Executive Direc...

2024-04-25 02:24:51 ET More on AstraZeneca: AstraZeneca: What The Market's Missing What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 Liquid biopsy firm Angle signs new commercial agreeme...

2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...

2024-04-17 01:50:40 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...